Adalvo today announced that it has entered into a partnership with AmbioPharm, a US-based pharmaceutical company, for an exclusive collaboration on the co-development and licensing for the commercialization of several complex pharmaceutical products in key global markets. The strategic partnership further enhances Adalvo’s product offering for global commercial partners and brings together complementary capabilities with AmbioPharm.
The partnership includes a basket of difficult-to-make peptide products that will be used to treat various diseases, ranging from diabetes to immunology disorders, cardiologic and endocrinology diseases as well as providing one-of-a-kind alternatives for highly orphan medications, which will now be affordable to patients in high demand of these products. Annual sales of the basket exceed $3 billion in the EU/ROW regions.
Adalvo’s General Manager Anil Okay commented: “We are extremely pleased to partner with AmbioPharm to further enhance our offering in peptide pharmaceuticals for patients and partners around the world. AmbioPharm is a highly respected and specialized organization in the field of peptide commercial manufacturing, with facilities around the world and is truly an ideal partner for us. We are on an exciting journey at Adalvo as we continue to strive to be always on target for our partners.”
Whilst the terms of the transaction are not being disclosed, Adalvo will assume responsibility for cross-fertilization of the products to all key global regions (excl. U.S. and China), while AmbioPharm will provide full-scale development background as one of the most competitive developers of peptide assets in the world.
Chris Bai, CEO of AmbioPharm said: “We are very pleased to partner with Adalvo, a global pharmaceutical company, specialized in sales and marketing of specialty drugs worldwide. AmbioPharm will focus on developing and manufacturing peptide APIs and drugs.”